Potential use of Oncostatin M in Critically ill Patients with acute Kidney Injury

1 Makris K, Spanou L. Acute kidney injury: Definition, pathophysiology and clinical phenotypes. Clin Biochem Rev. 2016;37(2):85-98. PMid:28303073 Search in Google Scholar

2 Magno AL, Herat LY, Carnagarin R, Schlaich MP, Matthews VB. Current knowledge of IL-6 cytokine family members in acute and chronic kidney disease. Biomedicines. 2019;7(1):19. https://doi.org/10.3390/biomedicines7010019 PMid:30871285 Search in Google Scholar

3 Luyckx VA, Cairo LV, Compston CA, Phan WL, Mueller TF. Oncostatin M pathway plays a major role in the renal acute phase response. Am J Physiol Renal Physiol. 2009;296(4):F875-83. https://doi.org/10.1152/ajprenal.90633.2008 PMid:19158344 Search in Google Scholar

4 Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, Galun E, et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol. 2008;19(6):1106-15. https://doi.org/10.1681/ASN.2007070744 PMid:18337485 Search in Google Scholar

5 Gong Y, Yan X, Sun X, Chen T, Liu Y, Cao J. Oncostatin M Is a prognostic biomarker and inflammatory mediator for sepsis. J Infect Dis. 2020;221(12):1989-98. https://doi.org/10.1093/infdis/jiaa009 PMid:31930328 Search in Google Scholar

6 West NR, Hegazy AN, Owens BM, Bullers SJ, Linggi B, Buonocore S, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(5):579-89. https://doi.org/10.1038/nm.4307 PMid:28368383 Search in Google Scholar

7 O’Hara KA, Kedda MA, Thompson PJ, Knight DA. Oncostatin M: An interleukin-6-like cytokine relevant to airway remodelling and the pathogenesis of asthma. Clin Exp Allergy. 2003;33(8):1026-32. https://doi.org/10.1046/j.1365-2222.2003.01714.x PMid:12911774 Search in Google Scholar

8 Midhuna K, Adole PS, Vinod KV, Balamurugan N. Association of serum regenerating islet-derived protein 3-beta and oncostatin-M levels with the risk of acute coronary syndrome in patients with type 2 diabetes mellitus-a pilot study. Diabetes Metab Syndr. 2020;14(5):1087-92. https://doi.org/10.1016/j.dsx.2020.06.026 PMid: 32652496 Search in Google Scholar

9 Hoste EA, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, et al. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol. 2018;14(10):607-25. https://doi.org/10.1038/s41581-018-0052-0 PMid:30135570 Search in Google Scholar

10 Pothoven KL, Norton JE, Hulse KE, Suh LA, Carter RG, Rocci E, et al. Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease. J Allergy Clin Immunol. 2015;136(3):737-46.e4. https://doi.org/10.1016/j.jaci.2015.01.043 PMid:25840724 Search in Google Scholar

11 Liang H, Block TM, Wang M, Nefsky B, Long R, Hafner J, et al. Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark. 2012;11(4):161-71. https://doi.org/10.3233/CBM-2012-00276 PMid:23144154 Search in Google Scholar

12 Den Hoedt CH, Bots ML, Grooteman MP, Van Der Weerd NC, Mazairac AH, Penne EL, et al. Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney Int. 2014;86(2):423-32. https://doi.org/10.1038/ki.2014.9 PMid:24552852 Search in Google Scholar

13 Nakada TA, Oda S, Matsuda KI, Sadahiro T, Nakamura M, Abe R, et al. Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med. 2008;14(5):257-63. https://doi.org/10.2119/2007-00108.Nakada PMid:18327291 Search in Google Scholar